| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() American Academy of Dermatology Association Issues Updated Position Statement on Isotretinoin SCHAUMBURG, Ill -- November 25, 2010 -- The American Academy of Dermatology Association (AADA) recently updated its position statement on the use of isotretinoin. The position continues to state that patient safety is dermatologists’ primary concern and that the AADA is committed to the safe and responsible use of isotretinoin, which is the most effective treatment for severe acne. “Isotretinoin continues to be considered a critically important drug for treating patients with severe acne who fail other therapies,” said William D. James, MD, president of the AADA and its sister organization, the American Academy of Dermatology (AAD). “Isotretinoin offers our patients with severe acne significant, life-changing benefits. Providing this medicine safely is our top priority.” The updated position states: The position statement concludes that the prescription of isotretinoin for severe nodular acne continues to be appropriate as long as prescribing physicians are aware of the issues related to isotretinoin use. “Physicians should to be alert to potential concerns, including IBD or psychiatric disturbance, educate their patients about these and other potential risks, and monitor their patients for any indication of these symptoms,” said Dr. James. To access the complete position statement on isotretinoin, visit http://www.aad.org/forms/policies/Uploads/PS/PS-Isotretinoin.pdf
SOURCE: American Academy of Dermatology Association
|